Not that simple. UK is a lousy oncology market, only 1/10th the size of the U.S. And the UK payers are loath to pay for very pricey personalized oncology treatments. CAR-T, a very successful blood cancer treatment, took over 5 years to get any UK government reimbursement, only from the NICE charity for a very limited number of patients. So even if DCVax-L gets approved, the access to patients is very likely to be very limited. This makes it very challenging for NWBO to make a a profit -- compassionate care at cost of goods likely. That leaves NWBO very challenged to survive for more than a few years.
U.S. FDA has clearly already told NWBO they won't accept their P3 trial and will require another onerous trial that will take years again.
This is not a very positive scenario and one that is likely if MHRA approves DCVax-L. If not, NWBO falls back on being the Advent contract manufacturer.
Market Data 
Markets 
AI
